Neoplasms

Symptoms and General Pathology

All Conditions

Skin and Connective Tissue Diseases

Nervous System Diseases

Rare Diseases

Neoplasm Metastasis

Melanoma

Brain Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Ipilimumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

* Ipilimumab at 3 mg/kg IV over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
* Nivolumab at 1 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle for 4 cycles, then at 240 mg IV over 30 minutes on Days 1 and 15 of each 28-day cycle for up to 20 doses
* Within 2 weeks of the start of ipilimumab (before or after), treatment with Optune will begin. All patients will be required to shave their heads to initiate array placement and Optune therapy.
* Treatment may continue for up to 1 year

-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.

Optune

George Ansstas, M.D.

This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis. The data of this study will also inform whether this combination will offer advantage in progression free survival (PFS) and overall survival.

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

* The PFS time will be calculated as the duration of time from the date of first dose of study treatment to the date of earliest intracranial progression or death, whichever occurs first.
* Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).

-Defined as the duration of time from the date of first dose of study treatment to death from any cause.

* Defined as the percentage of patients with a confirmed intracranial complete or partial response
* Using modified RANO criteria

* Defined as the percentage of patients with a confirmed extracranial complete or partial response
* Using modified RANO criteria

* Defined as the duration of time from the date of first dose of study treatment to the date of earliest extracranial progression or death, whichever occurs first. Patients who neither progress nor die by the data cutoff date will be censored at the last follow up.
* Using modified RANO criteria

-The descriptions and grading scales found in CTCAE version 5.0.

NovoCure Ltd.

Washington University School of Medicine

Optune + Ipilimumab + Nivolumab

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

The study was opened to enrollment from 07/01/2019 through 03/09/2022. The study was terminated early due to low enrollment. The low enrollment was due to the COVID-19 pandemic and no external referrals for the trial. The Principal Investigator reached out to other academic institutions about opening the trial but there was not any interest.

Dr. George Ansstas

Intracranial Progression-free Survival

Overall Survival

Best Intracranial Response Rate

Best Extracranial Response Rate

Extracranial Progression-free Survival

Safety of the Treatment Regimen as Measured by Number of Participants With Treatment-related Grade 3 or Greater Adverse Events

Safety of the Treatment Regimen as Measured by Number of Participants With Discontinuations Due to Treatment Related Adverse Events.

Overall Study

Behaviors and Mental Disorders

Glioblastoma

Glioma

Astrocytoma

Neoplasms, Neuroepithelial

Neoplasms, Glandular and Epithelial

Quality of Life

Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device

We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.

NovoTTF

Katherine B Peters, MD, PhD

This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).

Patients will be provided with a Fitbit Charge HR™, which they will begin wearing immediately to collect baseline information. The study team will teach the patients how to use the Fitbit and the associated smart phone application. Patients will also set an account with a platform that will provide information from the Fitbit (number of steps, sleep behaviors, and exercise log) to the study team. Patients will also have blood drawn, do a 6-minute walk test, and complete questionnaires at clinic visits 1, 8, 16, and 24 weeks after receiving the Fitbit. At the end of the study, patients will return the Fitbit to the study team.

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

ACTION: A Longitudinal Observational Study of Quality of Life, Functional Capacity and Physical Function in Glioblastoma Patients Treated With Tumor-Treating Fields

Mean change between baseline and week 24 in total physical activity (MET-h/wk) as measured by the Godin Leisure Time Questionnaire

Mean change from baseline at week 24 in subscales of the Functional Assessment of Cancer Therapy Brain (FACT-Br) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F)

Mean change from baseline at week 24 in sleep quality as measured by the Pittsburgh Sleep Quality Assessment (PSQI)

Mean change from baseline at week 24 in mood as measured by the Beck Depression Inventory (BDI)

Mean change from baseline at week 24 in functional capacity as measured by the 6-minute walk test

Mean change from baseline at week 8, 16, and 24 in the average daily number of steps as measured by the Fitbit among patients treated with Novo TTF

Duke University

Recurrence

Central Nervous System Depressants

Anesthetics

Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.

For further information see www.optune.com

A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.

Craniectomy

Anders R Korshoej, MD

The present study proposes a new and potentially superior clinical approach to Optune™ therapy of selected glioblastoma patients. The approach is based on combining TTFields with targeted surgical skull remodeling, such as minor craniectomy or a distribution of burr holes, designed for the individual patient. Pre-clinical modeling results suggest that such procedures may enhance the induced electrical field strength by up to \~100% and thereby potentially improve the clinical outcome of treated patients to a significant extent.

The study is an open label phase 1 clinical pilot experiment designed to investigate feasibility, safety and efficacy of the concept. Fifteen patients with first recurrence of glioblastoma will be included in the trial. All patients will receive TTFields therapy with targeted craniotomy and best physician's choice chemotherapy.

Enhancing Optune Therapy With Targeted Craniectomy

Enhancing Optune Therapy of Recurrent Glioblastoma Multiforme Using Targeted Surgical Skull Remodeling

Aarhus University Hospital

Anti-Infective Agents

Vaccines

Immunomodulating Agents

Poly I-C

Poly ICLC

Interferons

Immunologic Factors

MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields

Poly-ICLC

an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM

Tumor Treating Fields

synthetic long peptides (SLP) as vaccine substrate

Peptides

Adilia Hormigo, MD, PhD

The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields).

The study is designed to determine whether this treatment combination is well tolerated and safe.

This is a single-arm, single institution phase 1a / 1b study to test the safety, tolerability, and immunogenicity of MTA-based personalized vaccine in patients with newly diagnosed GBM along with the use of continual TTFields. MTA-based personalized vaccine is prepared in the laboratory with several peptides based on each patient's own tumor sequence.

The vaccine is given after the radiation and chemotherapy portion of the treatment, in the maintenance phase of temozolomide in conjunction with the TTFields.

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)

Feasibility administration of one vaccine; toxicity will be measured by severity of Adverse events with toxicity grading defined by Cancer Therapy Evaluation Program's (CTEP) v4.0 of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale

Safety will be measured by number of Adverse events with toxicity grading defined by Cancer Therapy Evaluation Program's (CTEP) v4.0 of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale

Overall response as measured by RANO (Response assessment in neuro-oncology) Response Criteria: Complete response, Partial response, Stable Disease, and Progressive Disease

Albert Einstein College of Medicine

Disease Progression

Temozolomide

APG-157 is an orally administered drug encased in a hydrogel pastille.

Arms:

* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)
* Progression post TMZ (will receive APG-157 only)
* Ongoing Optune (will receive concurrent Optune + APG-157)
* Progression post Optune (will receive APG-157 only)

APG-157

Dedra L Preece, BS

Theresa Strakos, BS

Ekokobe Fonkem, DO

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

Glioblastoma patients with disease recurrence after primary, currently approved primary treatments have limited options. Therefore, this expanded access trial is designed to test a new therapeutic option for these patients.

Patients who have progressed on a combination of both Temozolomide and Tumor Treating Field (Optune) or as single treatment Temozolomide (TMZ) OR Tumor Treating Fields (Optune) are eligible to receive APG-157. During APG-157 dosing, TMZ or Optune may be concurrently given at the decision of the Principal Investigator. APG-157 will be given until disease progression or intolerance by the patient.

Radiation followed by adjuvant Temozolomide for 6 to 12 months which is a current standard of care (SOC). Upon progression of this disease after SOC treatment, there are very limited further options for these patients. This expanded access administration will evaluate the potential of APG-157, a novel drug under development for head and neck cancer, as a potential treatment for these recurrent glioblastoma patients.

Brief Description of Objectives:

* Improve six-month progression-free survival (PFS) and overall survival (OS) of the patients eligible for the treatment under Expanded Access protocol.
* Improvement in Quality of Life
* Achievements of above two objectives without any Serious Adverse Events (SAEs) and adverse drug-drug interactions.

Brief Description of Plans for Efficacy Assessment:

* Improvement in Quality of Life
* Efficacy will be assessed using Imaging (objective tumor response using Response Assessment in Neuro-Oncology criteria (RANO), hematological assessment, and tolerance.

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Aveta Biomics, Inc.

Antineoplastic Agents, Alkylating

Alkylating Agents

Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).

Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).

Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.

Philip A Arlen, PhD

William Fisher

Nicholas Avgeropoulos, MD

An Open-Label, Multi-Center Study to Assess the Safety and Pharmacokinetics of BRCX014 Combined with Standard-of-Care Treatment in Subjects with Glioblastoma

Several studies have shown a possible anti-tumor role for cannabinoids by modulating cell signaling pathways, inhibiting angiogenesis, inducing apoptosis, and overcoming chemotherapy resistance. The investigators seek to demonstrate the safety profile of BRCX014, a cannabinoid formulation, when given to glioblastoma patients in conjunction with standard-of-care therapy.

This study consists of dose escalations that follow the standard 3+3 design, proceeding until the maximum tolerated dose is attained. The treatment period for patients in this study at each dose will be one year.

A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma

A Phase I Study of BRCX014 to Investigate Dose-Ranging Safety and Pharmacokinetics in Adults With Glioblastoma (GBM) and Non-Methylated MGMT Gene Status

The primary objective of this study is to evaluate the safety and tolerability of BRCX014 using clinical assessments and lab results.

A secondary objective of this study is to identify the maximum tolerated dose of BRCX014.

A secondary objective of this study is to perform pharmacokinetics analyses by measuring the plasma concentrations of BRCX014, temozolomide, and their major metabolites using lab results.

A secondary objective of this study is to measure PFS using lab results and radiographic data.

Leaf Vertical Inc.

Gliosarcoma

Bevacizumab

Angiogenesis Inhibitors

Growth Inhibitors

Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.

10 mg/kg every 2 weeks intravenously over 30 minutes.

Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.

TTFields Therapy

Manmeet Ahluwalia, MD, FACP

This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields \[TTFields\] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.

Patients that have recurrent glioblastoma that has progressed on bevacizumab continue to receive bevacizumab with the addition of Tumor Treating Fields Therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma

Number of participants alive at 6 months. Out of the planned 80 eligible patients, if 36 or more were alive at six months then the null hypothesis that the six-month survival rate is 35% or less would be rejected, concluding that the six-month survival is at least 35%. No testing was done due to the small number of participants resulting from early study closure.

Survival time is defined as time from registration the to date of death from any cause or last known follow-up (censored) and was to be estimated by the Kaplan-Meier method. Given the small number of participants due to early study closure, only the number of patients last reported to be alive at time of study termination is reported.

Progression is defined by the Modified Response Assessment in Neuro-Oncology (RANO) Response Criteria. (The precise definition is too long to be included here.) Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up. Progression-free survival rates were to be estimated using the Kaplan-Meier method. Given the small number of participants due to early study closure, only the number of patients last reported to be alive without progression at time of study termination is reported.

Modified Response Assessment in Neuro-Oncology (RANO) Response Criteria was used to define response and progression. (The precise definitions are too long to be included here.) Objective response is defined as complete or partial response. The percentage of participants with objective response was to be estimated using the exact binomial method with accompanying 95% confidence intervals. Given the small number of participants due to early study closure, only the number of patients with objective response is reported.

Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the adverse event (AE). The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. The percentage of participants with grade 3 or higher treatment-related adverse events was to be estimated using the exact binomial method with accompanying 95% confidence intervals.

RTOG Foundation, Inc.

Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.

Bevacizumab: 10 mg/kg every 2 weeks intravenously over 30 minutes.

TTFields Therapy: Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.

Bevacizumab and TTFields Therapy

This study stopped accrual early due to unmet targeted accrual goals with 3 subjects accrued out of 85 planned.

Wendy Seiferheld

Overall Survival at 6 Months

Overall Survival (OS)

Progression-Free Survival

Number of Participants With Partial or Complete Response

Number of Participants With Grade 3+ Treatment-related Adverse Events

Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.

Patients will be given temozolomide according to routine treatment dosing and schedule.

Patients will be given radiation therapy according to routine treatment dosing and schedule.

Radiation Therapy

Ricky Chen, MD

The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and schedule.

The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and schedule.

The expected toxicity is skin related, and patients will be followed closely with weekly skin and neurological examinations during radiation therapy and for 8 weeks afterwards to capture any delayed toxicity as they begin adjuvant therapy per routine treatment. As long as study treatment is tolerated and their conditions remain stable, patients will continue the treatment for up to 24 months.

Prior to enrollment, an exploratory analysis of radiation dosimetry will be performed by phantom modeling incorporating the Optune arrays. The study incorporates three stages of recruitment to confirm the safety of combining tumor treating fields therapy with concurrent chemoradiation: a safety lead-in cohort of the first 6 patients enrolled, a second safety lead-in cohort of 9 patients, and an expansion cohort with 15 additional patients.

The study is an open-label pilot study. Following surgery, eligible patients will start tumor treating fields therapy with the Optune device less than 2 weeks prior to radiation and temozolomide given at a dose and schedule conforming to routine treatment.

Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM

Safety and Tolerability of Tumor Treating Fields (TTFields) Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)

Number of patients who experienced a treatment-related adverse event

Number of patients who experienced a treatment-related serious adverse event based on the NCI Common Terminology Criteria for Adverse Events (version 4.03)

Number of patients alive at Day 106 (15 weeks), end of main study period

Number of patients who are progression free at 6 months and 24 months. Progression is defined as any of the following: greater than or equal to 25% increase in sum of lesions compared with smallest tumor measurement obtained, significant increase in T2/FLAIR non-enhancing lesions, any new lesion, clear clinical deterioration not attributable to other causes, or clear progression of non-measureable disease.

University of California, San Francisco

Providence Health & Services

Participants who finished the DLT period and were assessed by investigators

Safety lead-in Cohort

The Karnofsky Performance Scale Index allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Karnofsky Performance Scale (KPS)

Newly diagnosed patients histologically confirmed glioblastoma after maximally safe resection

Early termination leading to small numbers of subjects analyzed

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis	NCT03903640	Melanoma With B...	Optune Nivolumab Ipilimumab	18 Years -	Washington University School of Medicine
Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields	NCT03501134	Malignant Gliom...	NovoTTF	18 Years -	Duke University
Enhancing Optune Therapy With Targeted Craniectomy	NCT02893137	Glioblastoma	Optune Craniectomy	18 Years -	University of Aarhus
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma	NCT03223103	Glioblastoma	Poly-ICLC Tumor Treating ... Peptides	18 Years -	Albert Einstein College of Medicine
Treatment of Recurrent GBM With APG-157 Via Expanded Access	NCT05551013	Glioblastoma Glioblastoma Mu...	APG-157	18 Years - 85 Years	Aveta Biomics, Inc.
A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma	NCT03687034	Glioblastoma	Temozolomide Optune	18 Years - 85 Years	Leaf Vertical Inc.
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma	NCT02743078	Glioblastoma Glioma Gliosarcoma	Bevacizumab TTFields Therap...	22 Years -	RTOG Foundation, Inc.
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis	NCT03903640	Melanoma With B...	Optune Nivolumab Ipilimumab	18 Years -	Washington University School of Medicine
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM	NCT03705351	Glioblastoma Cancer of Brain Glioblastoma Mu... Brain Tumor	Tumor Treating ... Temozolomide Radiation Thera...	22 Years -	Providence Health & Services
Treatment of Recurrent GBM With APG-157 Via Expanded Access	NCT05551013	Glioblastoma Glioblastoma Mu...	APG-157	18 Years - 85 Years	Aveta Biomics, Inc.
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma	NCT02663271	Glioblastoma Mu... Glioblastoma Malignant Gliom... GBM	Bevacizumab Optune Brain MRI Quality of Life...	22 Years -	University of Florida
TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine	NCT04671459	Glioblastoma Mu... Recurrent Gliob...	TTFields and SR...	18 Years -	Prof. Franciszek Lukaszczyk Memorial Oncology Center
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma	NCT04474353	Glioblastoma Newly Diagnosed...	Optune Gadolinium Temozolomide Stereotactic ra...	18 Years -	Stanford University

Spots Global Cancer Trial Database for optune

Every month we try and update this database with for optune cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for optune

Every month we try and update this database with for optune cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for optune cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.